Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LXRX Lexicon Pharmaceuticals	$0.91 -0.6%	$0.71	$0.28 ▼ $2.45	$325.70M	1.13	6.84 million shs	1.65 million shs
OSMT Osmotica Pharmaceuticals		$1.16	$0.98 ▼ $4.95	$69.47M	2.34	396,682 shs	296,500 shs
SNDX Syndax Pharmaceuticals	$9.28 +3.1%	$10.50	$8.58 ▼ $25.07	$774.42M	0.7	1.84 million shs	817,852 shs
SYRS Syros Pharmaceuticals	$0.03 +2.0%	$0.03	$0.02 ▼ $6.93	$673K	1.31	8.06 million shs	44,922 shs
WVE WAVE Life Sciences	$6.97 +3.3%	$6.72	$5.04 ▼ $16.74	$1.08B	-1.01	1.28 million shs	652,460 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LXRX Lexicon Pharmaceuticals	0.00%	+10.85%	+37.65%	+117.24%	-45.18%
OSMT Osmotica Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
SNDX Syndax Pharmaceuticals	0.00%	+2.61%	-15.36%	-17.55%	-53.80%
SYRS Syros Pharmaceuticals	0.00%	-16.05%	0.00%	+5.46%	-99.50%
WVE WAVE Life Sciences	0.00%	+4.50%	+4.34%	+15.59%	+31.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LXRX Lexicon Pharmaceuticals	2.5175 of 5 stars	3.2	3.0	0.0	0.0	1.4	2.5	0.6
OSMT Osmotica Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	3.1516 of 5 stars	3.5	1.0	0.0	4.4	1.2	0.0	0.0
SYRS Syros Pharmaceuticals	4.3567 of 5 stars	3.1	5.0	0.0	4.3	1.1	2.5	0.6
WVE WAVE Life Sciences	4.3704 of 5 stars	3.5	1.0	0.0	4.8	2.0	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LXRX Lexicon Pharmaceuticals	2.40	Hold	$3.67	302.93% Upside
OSMT Osmotica Pharmaceuticals	0.00	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	2.90	Moderate Buy	$35.80	285.94% Upside
SYRS Syros Pharmaceuticals	2.20	Hold	$3.33	13,180.21% Upside
WVE WAVE Life Sciences	2.92	Moderate Buy	$20.50	194.12% Upside

Current Analyst Ratings Breakdown

Latest LXRX, OSMT, SYRS, SNDX, and WVE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	LXRX Lexicon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
6/23/2025	WVE WAVE Life Sciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$18.00
6/11/2025	WVE WAVE Life Sciences	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$14.00
5/6/2025	SNDX Syndax Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$16.00 ➝ $17.00
5/6/2025	SNDX Syndax Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/29/2025	WVE WAVE Life Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$10.00
4/8/2025	WVE WAVE Life Sciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$18.00

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LXRX Lexicon Pharmaceuticals	$31.08M	10.58	N/A	N/A	$0.40 per share	2.28
OSMT Osmotica Pharmaceuticals	$177.88M	0.00	N/A	1.00	$1.50 per share	0.00
SNDX Syndax Pharmaceuticals	$43.72M	18.26	N/A	N/A	$3.38 per share	2.74
SYRS Syros Pharmaceuticals	$386K	1.74	N/A	N/A	$0.79 per share	0.03
WVE WAVE Life Sciences	$108.30M	10.01	N/A	N/A	$1.37 per share	5.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LXRX Lexicon Pharmaceuticals	-$200.40M	-$0.51	N/A	N/A	N/A	-568.04%	-103.16%	-54.95%	7/30/2025 (Estimated)
OSMT Osmotica Pharmaceuticals	-$79.59M	-$1.59	N/A	N/A	N/A	-138.76%	-81.23%	-20.97%	N/A
SNDX Syndax Pharmaceuticals	-$318.76M	-$3.86	N/A	N/A	N/A	-757.53%	-101.60%	-58.41%	8/7/2025 (Estimated)
SYRS Syros Pharmaceuticals	-$164.57M	-$3.03	N/A	N/A	N/A	N/A	-3,369.56%	-97.04%	7/29/2025 (Estimated)
WVE WAVE Life Sciences	-$97.01M	-$0.84	N/A	N/A	N/A	N/A	-86.49%	-37.20%	8/6/2025 (Estimated)

Latest LXRX, OSMT, SYRS, SNDX, and WVE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	LXRX Lexicon Pharmaceuticals	-$0.10	-$0.07	+$0.03	-$0.07	$1.26 million	$1.26 million
5/8/2025	Q1 2025	WVE WAVE Life Sciences	-$0.27	-$0.29	-$0.02	-$0.29	$11.65 million	$9.18 million
5/5/2025	Q1 2025	SNDX Syndax Pharmaceuticals	-$1.04	-$0.98	+$0.06	-$0.98	$15.88 million	$20.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LXRX Lexicon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OSMT Osmotica Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SYRS Syros Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
WVE WAVE Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LXRX Lexicon Pharmaceuticals	0.48	2.22	2.22
OSMT Osmotica Pharmaceuticals	N/A	0.43	0.42
SNDX Syndax Pharmaceuticals	1.53	5.80	5.75
SYRS Syros Pharmaceuticals	N/A	2.25	2.25
WVE WAVE Life Sciences	N/A	2.95	2.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LXRX Lexicon Pharmaceuticals	74.70%
OSMT Osmotica Pharmaceuticals	46.18%
SNDX Syndax Pharmaceuticals	N/A
SYRS Syros Pharmaceuticals	91.47%
WVE WAVE Life Sciences	89.73%

Insider Ownership

Company	Insider Ownership
LXRX Lexicon Pharmaceuticals	13.90%
OSMT Osmotica Pharmaceuticals	5.22%
SNDX Syndax Pharmaceuticals	4.10%
SYRS Syros Pharmaceuticals	12.26%
WVE WAVE Life Sciences	23.98%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LXRX Lexicon Pharmaceuticals	140	361.49 million	311.25 million	Optionable
OSMT Osmotica Pharmaceuticals	302	62.59 million	59.32 million	Not Optionable
SNDX Syndax Pharmaceuticals	110	86.05 million	82.52 million	Optionable
SYRS Syros Pharmaceuticals	120	26.83 million	23.54 million	Optionable
WVE WAVE Life Sciences	240	155.56 million	118.26 million	Optionable

LXRX, OSMT, SYRS, SNDX, and WVE Headlines

Recent News About These Companies

Moody Aldrich Partners LLC Increases Holdings in WAVE Life Sciences Ltd. (NASDAQ:WVE)

July 4 at 6:43 AM | marketbeat.com

H.C. Wainwright Reaffirms Buy Rating on Wave Life Sciences After ADA Data Release

July 3 at 7:06 PM | msn.com

Where WAVE Life Sciences Stands With Analysts

June 23, 2025 | benzinga.com

WAVE Life Sciences (NASDAQ:WVE) Receives "Outperform" Rating from Wedbush

June 23, 2025 | marketbeat.com

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA ...

June 22, 2025 | manilatimes.netM

Wave Life Sciences Presents Promising Preclinical Data for WVE-007, a Novel siRNA Obesity Treatment at American Diabetes Association Meeting

June 22, 2025 | nasdaq.com

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ...

June 20, 2025 | finance.yahoo.com

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions

June 20, 2025 | globenewswire.com

WAVE Life Sciences (NASDAQ:WVE) Stock Price Down 6.8% - Should You Sell?

June 20, 2025 | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Shares Cross Below 50-Day Moving Average - Time to Sell?

June 19, 2025 | marketbeat.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Director Sells $208,500.00 in Stock

June 14, 2025 | insidertrades.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Director Gregory L. Verdine Sells 30,000 Shares

June 13, 2025 | marketbeat.com

Wave Life Sciences (NASDAQ:WVE) Now Covered by Raymond James

June 11, 2025 | marketbeat.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Receives Average Recommendation of "Buy" from Analysts

June 11, 2025 | marketbeat.com

Brokers Offer Predictions for WVE FY2026 Earnings

June 10, 2025 | marketbeat.com

Wave Life Sciences (NASDAQ:WVE) Shares Down 4.6% - Here's Why

June 9, 2025 | marketbeat.com

Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference

May 29, 2025 | globenewswire.com

Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer

May 28, 2025 | globenewswire.com

Is Wave Life Sciences (WVE) the Best Low Priced Biotech Stock to Buy Now?

May 13, 2025 | msn.com

Wave Life Sciences Ltd. (WVE) Q1 2025 Earnings Call Transcript

May 9, 2025 | seekingalpha.com

WAVE Life Sciences Ltd (WVE) Q1 2025: Everything You Need To Know Ahead Of Earnings

May 9, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXRX, OSMT, SYRS, SNDX, and WVE Company Descriptions

Lexicon Pharmaceuticals NASDAQ:LXRX

$0.91 -0.01 (-0.64%)

Closing price 07/3/2025 03:52 PM Eastern

Extended Trading

$0.91 0.00 (0.00%)

As of 07/3/2025 04:54 PM Eastern

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Osmotica Pharmaceuticals NASDAQ:OSMT

Osmotica Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ.

Syndax Pharmaceuticals NASDAQ:SNDX

$9.28 +0.28 (+3.07%)

Closing price 07/3/2025 03:59 PM Eastern

Extended Trading

$9.15 -0.13 (-1.36%)

As of 07/3/2025 04:20 PM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Syros Pharmaceuticals NASDAQ:SYRS

$0.03 +0.00 (+2.03%)

As of 07/3/2025 12:37 PM Eastern

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

WAVE Life Sciences NASDAQ:WVE

$6.97 +0.22 (+3.26%)

Closing price 07/3/2025 03:00 PM Eastern

Extended Trading

$6.97 0.00 (0.00%)

As of 07/3/2025 04:14 PM Eastern

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time